Want to join the conversation?
In 3Q15, excluding the impact of foreign currency, $BXLT's hematology & immunology businesses generated double-digit sales growth. Hematology revenues increased 10% to $935MM as it continues to focus on enhancing access and elevating standards of care worldwide; and Immunology sales advanced 12% to $626MM on a pro forma basis.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!